PhoreMost reaches milestone in a target discovery alliance with Boehringer Ingelheim

FHS
June 4, 2024
11:52 am

PhoreMost Ltd., has triggered a milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies, to transform patients’ lives.

Phare Bio receives funds to advance AI drug discovery platform

Phare Bio and Collins Lab are working to develop an inaugural open-source database dedicated to AI-driven antibiotic discovery. Credit: Gorodenkoff/Shutterstock. Phare Bio, in collaboration with

September 27, 2024

AI and Breast Cancer Screening; Cancer After Treatment for Sickle Cell

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange,

December 10, 2023

Whole Genome Sequencing Boosts Diagnosis of Rare Disease in Infants

Whole genome sequencing captured almost twice as many genetic abnormalities that may be responsible for disease in infants, compared with a standard targeted test, researchers

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.